Overview
Semaglutide is classified as a glp-1 agonist peptide. Fat loss, appetite control, cardiovascular benefits.
GLP-1 receptor agonism mimics the incretin hormone to reduce appetite, slow gastric emptying, improve insulin sensitivity, and provide cardiovascular protection.
Also known as: Ozempic, Wegovy, Rybelsus
Category
GLP-1 Agonist
Half-Life
168h
Route
SubQ
FDA Status
Approved
How Does Semaglutide Work?
GLP-1 receptor agonism mimics the incretin hormone to reduce appetite, slow gastric emptying, improve insulin sensitivity, and provide cardiovascular protection.
At the molecular level, Semaglutide operates through pathways characteristic of the GLP-1 Agonist class, interacting with target receptors and downstream signaling cascades to produce its observed effects.
Published Research
The following studies are indexed from PubMed and peer-reviewed journals:
[1]STEP 1: Semaglutide 2.4 mg for weight management
Wilding et al. (NEJM): Landmark STEP 1 trial semaglutide 2.4mg achieved 14.9% mean weight loss vs 2.4% placebo at 68 weeks in 1,961 adults with obesity.
Evidence: very strong[2]SELECT trial: semaglutide reduces cardiovascular events by 20%
Lincoff et al. (NEJM): SELECT trial shows semaglutide 2.4mg reduces major adverse cardiovascular events by 20% in overweight/obese adults with established CVD.
Evidence: very strong[3]STEP program overview: pooled Phase 3 weight loss data
Comprehensive analysis across STEP trials showing 14.9-17.4% weight loss, improved cardiometabolic risk factors, blood pressure, and quality of life with semaglutide 2.4mg.
Evidence: very strong[4]Oral semaglutide (Rybelsus) in type 2 diabetes PIONEER program
Aroda et al. (JAMA): PIONEER trials demonstrate oral semaglutide achieves significant HbA1c and weight reductions, representing the first oral GLP-1RA for type 2 diabetes.
Evidence: very strong[5]Semaglutide cognitive and neurological effects emerging research
Emerging evidence suggests semaglutide may have neuroprotective properties, with trials underway for Alzheimer's disease and other neurodegenerative conditions.
Evidence: emerging[6]Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes.
A study published in The New England journal of medicine investigating the effects and mechanisms.
Evidence: preclinical[7]Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design.
A study published in American heart journal investigating the effects and mechanisms.
Evidence: preclinical[8]GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art.
A study published in Molecular metabolism investigating the effects and mechanisms.
Evidence: preclinical[9]The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease.
A study published in Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association investigating the effects and mechanisms.
Evidence: moderate[10]Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies.
A study published in Diabetes, obesity & metabolism investigating the effects and mechanisms.
Evidence: moderate[11]Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis.
A study published in Metabolism: clinical and experimental investigating the effects and mechanisms.
Evidence: moderate[12]Obesity, Cardiovascular Disease, and the Promising Role of Semaglutide: Insights from the SELECT Trial.
A study published in Current problems in cardiology investigating the effects and mechanisms.
Evidence: moderate[13]Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial.
A study published in Diabetes care investigating the effects and mechanisms.
Evidence: moderate[14]The Weight-loss Effect of GLP-1RAs Glucagon-Like Peptide-1 Receptor Agonists in Non-diabetic Individuals with Overweight or Obesity: A Systematic Review with Meta-Analysis and Trial Sequential Analysis of Randomized Controlled Trials.
A study published in The American journal of clinical nutrition investigating the effects and mechanisms.
Evidence: moderate[15]Efficacy and safety of semaglutide 2.4 mg for weight loss in overweight or obese adults without diabetes: An updated systematic review and meta-analysis including the 2-year STEP 5 trial.
A study published in Diabetes, obesity & metabolism investigating the effects and mechanisms.
Evidence: moderate[16]Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
A study published in The American journal of cardiology investigating the effects and mechanisms.
Evidence: moderate[17]Emerging Role of GLP-1 Agonists in Obesity: A Comprehensive Review of Randomised Controlled Trials.
A study published in International journal of molecular sciences investigating the effects and mechanisms.
Evidence: moderate[18]Dose-response effects on HbA(1c) and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial.
A study published in Diabetologia investigating the effects and mechanisms.
Evidence: moderate[19]Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes : A Systematic Review of Randomized Controlled Trials.
A study published in Annals of internal medicine investigating the effects and mechanisms.
Evidence: moderate[20]Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction.
A study published in Cardiovascular diabetology investigating the effects and mechanisms.
Evidence: preclinicalSafety Profile
FDA-approved for diabetes (Ozempic) and obesity (Wegovy). Well-studied long-term. GI side effects possible. Prescription required.
| Side Effect | Incidence | Severity |
|---|---|---|
| Nausea | ~44% of users | moderate |
| Diarrhea | ~30% of users | mild |
| Vomiting | ~24% of users | moderate |
| Constipation | ~24% of users | mild |
| Pancreatitis | Rare (<1%) | rare |
Sourcing Semaglutide for Research
If you're looking to source Semaglutide for laboratory research, our vendor directory compares pricing, purity testing, and COA verification from independently vetted suppliers.
* Research vendor — verify your regional regulations before purchase.
Full Research Profile
Semaglutide — dosing, interactions, timelines & more
Comprehensive compound profile with sourcing information, stacking synergies, and outcome timelines.